Publications by Daniel S Dickerson

Publications by authors named "Daniel S Dickerson"

Page 1 of 1

A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.

Ahad Sabet Daniel S Dickerson Eugenia E Kunina Anna Lucia Buccarello Joëlle Monnet

Rheumatol Ther

April 2022

Article Synopsis

- The study aimed to evaluate the bioequivalence and safety of MSB11022, a proposed biosimilar to adalimumab, when administered through an autoinjector (AI) versus a pre-filled syringe (PFS).
- Involving 216 healthy volunteers, the study found that key pharmacokinetic measurements met the pre-defined equivalence margins, indicating similar serum concentration profiles for both delivery methods.
- Both delivery methods resulted in comparable safety and tolerability, with a few injection-site reactions, confirming that MSB11022 can be effectively delivered using either device.

View Article and Find Full Text PDF

A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers.

Melicent Peck Michael E Rothenberg Rong Deng Nicholas Lewin-Koh Gaohong She Daniel S Dickerson

Antimicrob Agents Chemother

June 2019

causes serious bacterial infections with high morbidity and mortality, necessitating the discovery of new antibiotics. DSTA4637S is a novel antibody-antibiotic conjugate designed to target intracellular that is not adequately eliminated by current standard-of-care antibiotics. DSTA4637S is composed of an anti- Thiomab human immunoglobulin G1 (IgG1) monoclonal antibody linked to a novel rifamycin-class antibiotic (4-dimethylaminopiperidino-hydroxybenzoxazino rifamycin [dmDNA31]) via a protease-cleavable linker.

View Article and Find Full Text PDF